DuPont de Nemours, Inc. Free cash flow decreased by 65.7% to $130.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 388.9%, from -$45.00M to $130.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $224.00M | $634.00M | $540.00M | -$42.00M | -$10.00M | $264.00M | -$286.00M | $111.00M | $339.00M | $621.00M | $286.00M | $425.00M | $430.00M | -$45.00M | $443.00M | $379.00M | $130.00M |
| QoQ Change | — | +183.0% | -14.8% | -107.8% | +76.2% | >999% | -208.3% | +138.8% | +205.4% | +83.2% | -53.9% | +48.6% | +1.2% | -110.5% | >999% | -14.4% | -65.7% |
| YoY Change | — | — | — | — | -104.5% | -58.4% | -153.0% | +364.3% | >999% | +135.2% | +157.7% | +25.4% | -30.8% | -115.7% | +4.2% | -11.9% | +388.9% |